Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
Zhiwei Chen(Shanghai Jiao Tong University), Meilin Liao(Shanghai Chest Hospital)
Cited by 4
Related Papers
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
|The Lancet Oncology|2014|948
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
The histone acetylranseferase h<scp>MOF</scp> acetylates <scp>Nrf</scp>2 and regulates anti‐drug responses in human non‐small cell lung cancer
|British Journal of Pharmacology|2014|109